上期的《Market Letter》简要提到藤泽药品工业公司生产的免疫抑制剂Prograf(tacrolimus;FK—506)已被日本中央药事审议会药务局批准,该产品还有待厚生省的最后批准。藤泽公司的发言人指出,价格的谈判必须在5月底前完成,在此以后该产品即可投放市场。该产品的第一适应症是用于肝脏移植,然而在日本的市场很小,每年仅30～40个病例。尽管本品的作用方式尚未完全被阐明,在很多方面类似于金制剂类免疫抑制剂和环 The last issue of “Market Letter” briefly mentioned that Prograf (tacrolimus; FK-506), an immunosuppressant produced by Fujisawa Pharmaceutical Industry Co., Ltd., was approved by the Pharmacological Board of the Central Pharmaceutical Council of Japan and is subject to the final approval of the Ministry of Health and Welfare. A spokesman for Fujisawa pointed out that price negotiations must be completed by the end of May and the product can be put on the market after that. The first indications of the product is for liver transplantation, however the market in Japan is very small, only 30 to 40 cases per year. Although the mode of action of this product has not yet been fully elucidated, in many ways similar to gold preparations immunosuppressant and ring